AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.
ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced...
The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly...
The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective,...
The mean of analysts price targets for Apogee Therapeutics Inc. (APGE) points to a 134% upside in the stock. While this highly sought-after metric has not proven reasonably...
